NASDAQ$AMED

Amedisys Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Amedisys reported strong Q3 2020 financial results, exceeding internal and external expectations and leading to increased full-year guidance.

Amedisys reported a net service revenue increase of $49.5 million to $544.1 million compared to 2019, and a net income attributable to Amedisys, Inc. of $72.0 million compared to $34.1 million in 2019. Adjusted net income attributable to Amedisys, Inc. was $74.6 million compared to $37.9 million in 2019. The company is integrating Aseracare and has paid down a portion of its debt.

  • Net service revenue increased to $544.1 million compared to $494.6 million in 2019.
  • Net income attributable to Amedisys, Inc. reached $72.0 million compared to $34.1 million in 2019.
  • Adjusted EBITDA was $75.7 million compared to $56.8 million in 2019.
  • Full year 2020 guidance ranges were increased.

Headline financials

Total Revenue

$544M

Previous: $495M+10.0%
EPS (adj)

$2.24

Previous: $1.15+94.8%
Capital Expenditures

$1.29M

Previous: $3.64M-64.5%
Free Cash Flow

$81.8M

Previous: $43.8M+86.7%
Net Income

$72M

Previous: $34.1M+110.9%
Operating Income

$63.3M

Previous: $46.8M+35.2%
Gross Profit

$246M

Previous: $206M+19.7%
Cash & Equivalents

$113M

Previous: $20.8M+443.9%
Total Assets

$1.6B

Previous: $1.21B+32.2%
Stock-Based Comp

$7.12M

Previous: $6.3M+13.1%

Revenue & EPS history

Amedisys · Revenue · Quarterly

$544M

Q3 2020+10%vs Q3 2019
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Forward guidance

Amedisys anticipates net service revenue to be in the range of $2.067 billion to $2.072 billion, adjusted EBITDA to be in the range of $269 million to $272 million, and adjusted diluted earnings per share to be in the range of $6.02 to $6.08.

Tailwinds

  • Net service revenue is anticipated to be in the range of $2.067 billion to $2.072 billion.
  • Adjusted EBITDA is anticipated to be in the range of $269 million to $272 million.
  • Adjusted diluted earnings per share is anticipated to be in the range of $6.02 to $6.08.
  • Guidance excludes the effects of any future acquisitions.
  • Based on an estimated 33.4 million shares outstanding.

Headwinds

  • Home health, hospice and personal care industries are highly competitive.
  • The industries are subject to intensive regulations.
  • Trends are subject to numerous factors, risks, and uncertainties.
  • Changes in existing federal and state laws or regulations.
  • Changes in Medicare and other medical payment levels.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports

Historical avg

-0.6%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-5.0%

Avg return

30 days after

46%

32 / 70 earnings

Positive

+25.6%

Q2 2014

Best reaction

-25.3%

Q3 2013

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025
Q2 2025+1.2%+1.0%
Q1 2025+0.2%-0.8%-1.6%
Q4 2024+0.1%+0.6%+1.5%
Q3 2024+0.9%-3.4%-10.4%
Q2 2024+0.0%+0.5%-0.2%
Q1 2024+0.0%+0.8%+5.5%
Q4 2023+0.9%+0.6%-1.6%
Q3 2023-0.8%-1.1%+1.8%
Q2 2023-0.6%-0.2%+2.5%
Q1 2023+4.2%+3.9%+2.8%
Q4 2022+5.4%+2.2%-23.6%
Q3 2022-9.0%-4.2%-10.7%
Q2 2022-3.8%+0.9%-4.5%
Q1 2022+0.4%-3.3%-10.5%
Q4 2021+5.8%+14.5%+18.4%
Q3 2021+0.1%+1.7%-20.2%
Q2 2021-22.8%-22.9%-29.3%
Q1 2021+0.2%
Q4 2020-6.2%
Q3 2020-1.9%
Q2 2020+3.7%
Q1 2020-3.3%
Q4 2019-2.1%
Q3 2019-1.5%
Q2 2019-1.9%
Q1 2019-6.3%
Q4 2018+0.0%
Q3 2018+17.3%
Q2 2018+11.1%
Q1 2018+7.2%
Q4 2017+2.3%
Q3 2017+4.8%
Q2 2017-20.9%
Q1 2017+4.4%
Q4 2016+4.7%
Q3 2016-10.1%
Q2 2016-7.1%
Q1 2016-7.0%
Q4 2015+12.3%
Q3 2015+10.8%
Q2 2015-3.2%
Q1 2015+6.0%
Q4 2014-5.4%
Q3 2014+16.2%
Q2 2014+25.6%
Q1 2014-1.0%
Q4 2013-10.0%
Q3 2013-25.3%
Q2 2013+17.8%
Q1 2013-2.8%
Q4 2012-8.7%
Q3 2012-5.0%
Q2 2012+12.5%
Q1 2012-1.2%
Q4 2011-0.6%
Q3 2011-23.8%
Q2 2011-10.7%
Q1 2011-6.4%
Q4 2010-8.0%
Q3 2010+1.3%
Q2 2010-7.9%
Q1 2009-4.3%
Q1 2010+2.6%
Q4 2007-1.3%
Q4 2009-1.3%
Q3 2008-5.7%
Q3 2009-5.7%
Q4 2008+7.6%
Q2 2008+7.6%
Q2 2009+7.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro